Intravenous immunoglobulin: Striving for appropriate use

International Archives of Allergy and Immunology

Volumn 140, Issue 3, 2006, Pages 185-198

  Kumar, Arvind ^a   Teuber, Suzanne S ^a   Gershwin, M Eric ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Immunoglobulin; Intravenous immunoglobulin; Standards; Therapeutic use; Toxicity

Indexed keywords

ACETYLSALICYLIC ACID; ALKYLATING AGENT; CARIMUNE; CHOLINESTERASE INHIBITOR; CORTICOSTEROID; COTRIMOXAZOLE; DEXAMETHASONE; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; PANGLOBULIN; PREDNISONE; STEROID; UNCLASSIFIED DRUG;

ACUTE BRAIN DISEASE; ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC STEM CELL TRANSPLANTATION; ANAPHYLAXIS; ASEPTIC MENINGITIS; BACKACHE; BLEEDING; BLOOD DONOR; CHEST TIGHTNESS; CHILL; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CRYOGLOBULINEMIA; CYTOMEGALOVIRUS INFECTION; DEMYELINATING NEUROPATHY; DERMATOMYOSITIS; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; EATON LAMBERT SYNDROME; ERYTHEMA INFECTIOSUM; FOOD AND DRUG ADMINISTRATION; GUILLAIN BARRE SYNDROME; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOLYSIS; HEPATITIS; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; HYPONATREMIA; HYPOTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE DEFICIENCY; INCLUSION BODY MYOSITIS; KIDNEY ALLOGRAFT; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LEG PAIN; MEDLINE; MOTOR NEUROPATHY; MUCOCUTANEOUS LYMPH NODE SYNDROME; MULTIPLE SCLEROSIS; MYALGIA; MYASTHENIA GRAVIS; NAUSEA; NEUTROPENIA; NONHUMAN; PARAPROTEINEMIA; PATIENT CARE; PHOTOTHERAPY; PLEURA EFFUSION; PRION DISEASE; PRIORITY JOURNAL; PRURITUS; PUBLICATION; REVIEW; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; STIFF MAN SYNDROME; STROKE; THORAX PAIN; THROMBOCYTOPENIA; THROMBOEMBOLISM; VOMITING; WHEEZING;

EID: 33745087167     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000093204     Document Type: Review

References (98)

1. Dickler HB, Gelfand EW: Current perspectives on the use of intravenous immunoglobulin. Adv Intern Med 1996;41:641-680.
2. Nowak-Wegrzyn A, Lederman HM: Supply, use, and abuse of intravenous immunoglobulin. Curr Opin Pediatr 1999;11:533-539.
3. Imbach P, Barandun S, d'Apuzzo V, Baumgartner C, Hirt A, Morell A, Rossi E, Schoni M, Vest M, Wagner HP: High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981;i:1228-1231.
4. Sacher RA: Intravenous immunoglobulin consensus statement. J Allergy Clin Immunol 2001;108:S139-S146.
5. Chen C, Danekas LH, Ratko TA, Vlasses PH, Matuszewski KA: A multicenter drug use surveillance of intravenous immunoglobulin utilization in US academic health centers. Ann Pharmacother 2000;34:295-299.
6. Wilson K, Hebert PC: The challenge of an increasingly expensive blood system. CMAJ 2003;168:1149-1150.
7. Lemieux R, Bazin R, Neron S: Therapeutic intravenous immunoglobulins. Mol Immunol 2005;42:839-848.
8. Quartier P, Debre M, De Blic J, de Sauverzac R, Sayegh N, Jabado N, Haddad E, Blanche S, Casanova JL, Smith CI, Le Deist F, de Saint Basile G, Fischer A: Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients. J Pediatr 1999;134:589-596.
9. Busse PJ, Razvi S, Cunningham-Rundles C: Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. J Allergy Clin Immunol 2002;109:1001-1004.
10. Eijkhout HW, van Der Meer JW, Kallenberg CG, Weening RS, van Dissel JT, Sanders LA, Strengers PF, Nienhuis H, Schellekens PT: The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial. Ann Intern Med 2001;135:165-174.
11. Umetsu DT, Ambrosino DM, Quinti I, Siber GR, Geha RS: Recurrent sinopulmonary infection and impaired antibody response to bacterial capsular polysaccharide antigen in children with selective IgG-subclass deficiency. N Engl J Med 1985;313:1247-1251.
12. Durandy A, Wahn V, Petteway S, Gelfand EW: Immunoglobulin replacement therapy in primary antibody deficiency diseases - maximizing success. Int Arch Allergy Immunol 2005; 136:217-229.
13. Chapel HM, Spickett GP, Ericson D, Engl W, Eibl MM, Bjorkander J: The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol 2000;20:94-100.
14. Durongpisitkul K, Gururaj VJ, Park JM, Martin CF: The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics 1995;96:1057-1061.
15. Oates-Whitehead RM, Baumer JH, Haines L, Love S, Maconochie IK, Gupta A, Roman K, Dua JS, Flynn I: Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev 2003: CD004000.
16. Terai M, Shulman ST: Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr 1997;131:888-893.
17. Burns JC, Capparelli EV, Brown JA, Newburger JW, Glode MP: Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J 1998;17:1144-1148.
18. Bass EB, Powe NR, Goodman SN, Graziano SL, Griffiths RI, Kickler TS, Wingard JR: Efficacy of immune globulin in preventing complications of bone marrow transplantation: a meta-analysis. Bone Marrow Transplant 1993; 12:273-282.
19. Klaesson S, Ringden O, Ljungman P, Aschan J, Hagglund H, Winiarski J: Does high-dose intravenous immune globulin treatment after bone marrow transplantation increase mortality in veno-occlusive disease of the liver? Transplantation 1995;60:1225-1230.
20. Ruutu T, Ljungman P, Brinch L, Lenhoff S, Lonnqvist B, Ringden O, Ruutu P, Volin L, Albrechtsen D, Sallerfors B, Ebeling F, Myllyla G: No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. The Nordic BMT Group. Bone Marrow Transplant 1997;19:233-236.
21. Sullivan KM, Storek J, Kopecky KJ, Jocom J, Longton G, Flowers M, Siadak M, Nims J, Witherspoon RP, Anasetti C, Appelbaum FR, Bowden RA, Buckner CD, Crawford SW, Deeg HJ, Hansen JA, McDonald GB, Sanders JE, Storb R: A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery. Biol Blood Marrow Transplant 1996;2:44-53.
22. Wolff SN, Fay JW, Herzig RH, Greer JP, Dummer S, Brown RA, Collins RH, Stevens DA, Herzig GP: High-dose weekly intravenous immunoglobulin to prevent infections in patients undergoing autologous bone marrow transplantation or severe myelosuppressive therapy. A study of the American Bone Marrow Transplant Group. Ann Intern Med 1993; 118:937-942.
23. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. N Engl J Med 1988;319:902-907.
24. Griffiths H, Brennan V, Lea J, Bunch C, Lee M, Chapel H: Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors. Blood 1989;73:366-368.
25. Boughton BJ, Jackson N, Lim S, Smith N: Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukaemia and secondary hypogammaglobulinaemia. Clin Lab Haematol 1995;17:75-80.
26. Molica S, Musto P, Chiurazzi F, Specchia G, Brugiatelli M, Cicoira L, Levato D, Nobile F, Carotenuto M, Liso V, Rotoli B: Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study. Haematologica 1996;81:121-126.
27. Imbach P, Wagner HP, Berchtold W, Gaedicke G, Hirt A, Joller P, Mueller-Eckhardt C, Muller B, Rossi E, Barandun S: Intravenous immunoglobulin versus oral corticosteroids in acute immune thrombocytopenic purpura in childhood. Lancet 1985;ii:464-468.
28. Blanchette V, Imbach P, Andrew M, Adams M, McMillan J, Wang E, Milner R, Ali K, Barnard D, Bernstein M, et al: Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet 1994;344:703-707.
29. Blanchette VS, Luke B, Andrew M, Sommerville-Nielsen S, Barnard D, de Veber B, Gent M: A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura. J Pediatr 1993;123:989-995.
30. Imholz B, Imbach P, Baumgartner C, Berchtold W, Gaedicke G, Gugler E, Hirt A, Hitzig W, Mueller-Eckhardt C, Wagner HP: Intravenous immunoglobulin (i.v. IgG) for previously treated acute or for chronic idiopathic thrombocytopenic purpura (ITP) in childhood: a prospective multicenter study. Blut 1988;56:63-68.
31. Hedlund-Treutiger I, Henter JI, Elinder G: Randomized study of IVIg and high-dose dexamethasone therapy for children with chronic idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol 2003;25:139-144.
32. George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, Blanchette VS, Bussel JB, Cines DB, Kelton JG, Lichtin AE, McMillan R, Okerbloom JA, Regan DH, Warrier I: Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996;88:3-40.
33. Jacobs P, Wood L, Novitzky N: Intravenous gammaglobulin has no advantages over oral corticosteroids as primary therapy for adults with immune thrombocytopenia: a prospective randomized clinical trial. Am J Med 1994;97:55-59.
34. Godeau B, Chevret S, Varet B, Lefrere F, Zini JM, Bassompierre F, Cheze S, Legouffe E, Hulin C, Grange MJ, Fain O, Bierling P: Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial. Lancet 2002;359:23-29.
35. Godeau B, Lesage S, Divine M, Wirquin V, Farcet JP, Bierling P: Treatment of adult chronic autoimmune thrombocytopenic purpura with repeated high-dose intravenous immunoglobulin. Blood 1993;82:1415-1421.
36. Bussel JB, Pham LC, Aledort L, Nachman R: Maintenance treatment of adults with chronic refractory immune thrombocytopenic purpura using repeated intravenous infusions of gammaglobulin. Blood 1988;72:121-127.
37. Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection. The National Institute of Child Health and Human Developments Intravenous Immunoglobulin Study Group. N Engl J Med 1991;325:73-80.
38. Spector SA, Gelber RD, McGrath N, Wara D, Barzilai A, Abrams E, Bryson YJ, Dankner WM, Livingston RA, Connor EM: A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. Pediatric AIDS Clinical Trials Group. N Engl J Med 1994;331:1181-1187.
39. Dalakas MC: Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA 2004;291:2367-2375.
40. van der Meche FG, Schmitz PI: A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. N Engl J Med 1992;326:1123-1129.
41. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Lancet 1997;349:225-230.
42. Fergusson D, Hutton B, Sharma M, Tinmouth A, Wilson K, Cameron DW, Hebert PC: Use of intravenous immunoglobulin for treatment of neurologic conditions: a systematic review. Transfusion 2005;45:1640-1657.
43. Raphael JC, Chevret S, Harboun M, Jars-Guincestre MC: Intravenous immune globulins in patients with Guillain-Barré syndrome and contraindications to plasma exchange: 3 days versus 6 days. J Neurol Neurosurg Psychiatry 2001;71:235-238.
44. Mendell JR, Barohn RJ, Freimer ML, Kissel JT, King W, Nagaraja HN, Rice R, Campbell WW, Donofrio PD, Jackson CE, Lewis RA, Shy M, Simpson DM, Parry GJ, Rivner MH, Thornton CA, Bromberg MB, Tandan R, Harati Y, Giuliani MJ: Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001;56:445-449.
45. Dyck PJ, Litchy WJ, Kratz KM, Suarez GA, Low PA, Pineda AA, Windebank AJ, Karnes JL, O'Brien PC: A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994;36:838-845.
46. Hughes R, Bensa S, Willison H, Van den Bergh P, Comi G, Illa I, Nobile-Orazio E, van Doorn P, Dalakas M, Bojar M, Swan A: Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001;50:195-201.
47. McCrone P, Chisholm D, Knapp M, Hughes R, Comi G, Dalakas MC, Illa I, Kilindireas C, Nobile-Orazio E, Swan A, Van den Bergh P, Willison HJ: Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 2003;10:687-694.
48. Azulay JP, Blin O, Pouget J, Boucraut J, Bille-Turc F, Carles G, Serratrice G: Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology 1994;44:429-432.
49. Federico P, Zochodne DW, Hahn AF, Brown WF, Feasby TE: Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology 2000;55:1256-1262.
50. Van den Berg LH, Kerkhoff H, Oey PL, Franssen H, Mollee I, Vermeulen M, Jennekens FG, Wokke JH: Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1995;59:248-252.
51. Leger JM, Chassande B, Musset L, Meininger V, Bouche P, Baumann N: Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain 2001;124:145-153.
52. Van den Berg-Vos RM, Franssen H, Wokke JH, Van den Berg LH: Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment. Brain 2002; 125:1875-1886.
53. Dalakas MC, Quarles RH, Farrer RG, Dambrosia J, Soueidan S, Stein DP, Cupler E, Sekul EA, Otero C: A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann Neurol 1996;40:792-795.
54. Comi G, Roveri L, Swan A, Willison H, Bojar M, Illa I, Karageorgiou C, Nobile-Orazio E, van den Bergh P, Swan T, Hughes R, Aubry J, Baumann N, Hadden R, Lunn M, Knapp M, Leger JM, Bouche P, Mazanec R, Meucci N, van der Meche F, Toyka K: A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. J Neurol 2002;249:1370-1377.
55. Dalakas MC, Fujii M, Li M, Lutfi B, Kyhos J, McElroy B: High-dose intravenous immune globulin for stiff-person syndrome. N Engl J Med 2001;345:1870-1876.
56. Jordan SC, Tyan D, Stablein D, McIntosh M, Rose S, Vo A, Toyoda M, Davis C, Shapiro R, Adey D, Milliner D, Graff R, Steiner R, Ciancio G, Sahney S, Light J: Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 2004;15:3256-3262.
57. Tyan DB, Li VA, Czer L, Trento A, Jordan SC: Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation 1994;57:553-562.
58. Glotz D, Antoine C, Julia P, Suberbielle-Boissel C, Boudjeltia S, Fraoui R, Hacen C, Duboust A, Bariety J: Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant 2002;2:758-760.
59. Gottstein R, Cooke RW: Systematic review of intravenous immunoglobulin in haemolytic disease of the newborn. Arch Dis Child Fetal Neonatal Ed 2003;88:F6-F10.
60. Miqdad AM, Abdelbasit OB, Shaheed MM, Seidahmed MZ, Abomelha AM, Arcala OP: Intravenous immunoglobulin G (IVIG) therapy for significant hyperbilirubinemia in ABO hemolytic disease of the newborn. J Matern Fetal Neonatal Med 2004;16:163-166.
61. Margulies M, Voto LS, Mathet E, Margulies M: High-dose intravenous IgG for the treatment of severe rhesus alloimmunization. Vox Sang 1991;61:181-189.
62. Voto LS, Mathet ER, Zapaterio JL, Orti J, Lede RL, Margulies M: High-dose gammaglobulin (IVIG) followed by intrauterine transfusions (IUTs): a new alternative for the treatment of severe fetal hemolytic disease. J Perinat Med 1997;25:85-88.
63. Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C: Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol 1997;41: 789-796.
64. Wolfe GI, Barohn RJ, Foster BM, Jackson CE, Kissel JT, Day JW, Thornton CA, Nations SP, Bryan WW, Amato AA, Freimer ML, Parry GJ: Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis. Muscle Nerve 2002;26:549-552.
65. Bain PG, Motomura M, Newsom-Davis J, Misbah SA, Chapel HM, Lee ML, Vincent A, Lang B: Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology 1996;47:678-683.
66. Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K: Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 1997;48:712-716.
67. Walter MC, Lochmuller H, Toepfer M, Schlotter B, Reilich P, Schroder M, Muller-Felber W, Pongratz D: High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol 2000;247:22-28.
68. Dalakas MC, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E: A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 2001;56:323-327.
69. Achiron A, Kishner I, Sarova-Pinhas I, Raz H, Faibel M, Stern Y, Lavie M, Gurevich M, Dolev M, Magalashvili D, Barak Y: Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Arch Neurol 2004;61:1515-1520.
70. Strasser-Fuchs S, Fazekas F, Deisenhammer F, Nahler G, Mamoli B: The Austrian Immunoglobulin in MS (AIMS) study: final analysis. Mult Scler 2000;6(suppl 2):S9-S13.
71. Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B: Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet 1997;349:589-593.
72. Sorensen PS: The effect on MRI of gamma-globulin treatment in relapsing multiple sclerosis. Mult Scler 2000;6(suppl 2):S14-S17.
73. Noseworthy JH, O'Brien PC, Weinshenker BG, Weis JA, Petterson TM, Erickson BJ, Windebank AJ, Whisnant JP, Stolp-Smith KA, Harper CM Jr, Low PA, Romme LJ, Johnson M, An KN, Rodriguez M: IV immunoglobulin does not reverse established weakness in MS. Neurology 2000;55:1135-1143.
74. Hommes OR, Sorensen PS, Fazekas F, Enriquez MM, Koelmel HW, Fernandez O, Pozzilli C, O'Connor P: Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet 2004;364:1149-1156.
75. Sorensen PS, Haas J, Sellebjerg F, Olsson T, Ravnborg M: IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS. Neurology 2004;63:2028-2033.
76. Sorensen PS, Fazekas F, Lee M: Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis. Eur J Neurol 2002;9:557-563.
77. Koduri PR, Kumapley R, Khokha ND, Patel AR: Red cell aplasia caused by parvovirus B19 in AIDS: use of i.v. immunoglobulin. Ann Hematol 1997;75:67-68.
78. Marchand S, Tchernia G, Hiesse C, Tertian G, Cartron J, Kriaa F, Boubenider S, Goupy C, Lecointe D, Charpentier B: Human parvovirus B19 infection in organ transplant recipients. Clin Transplant 1999;13:17-24.
79. Koduri PR, Kumapley R, Valladares J, Teter C: Chronic pure red cell aplasia caused by parvovirus B19 in AIDS: use of intravenous immunoglobulin - a report of eight patients. Am J Hematol 1999;61:16-20.
80. Nour B, Green M, Michaels M, Reyes J, Tzakis A, Gartner JC, McLoughlin L, Starzl TE: Parvovirus B19 infection in pediatric transplant patients. Transplantation 1993;56:835-838.
81. Moudgil A, Shidban H, Nast CC, Bagga A, Aswad S, Graham SL, Mendez R, Jordan SC: Parvovirus B19 infection-related complications in renal transplant recipients: treatment with intravenous immunoglobulin. Transplantation 1997;64:1847-1850.
82. Rayment R, Brunskill SJ, Stanworth S, Soothill PW, Roberts DJ, Murphy MF: Antenatal interventions for fetomaternal alloimmune thrombocytopenia. Cochrane Database Syst Rev 2005:CD004226.
83. Bussel JB, Berkowitz RL, McFarland JG, Lynch L, Chitkara U: Antenatal treatment of neonatal alloimmune thrombocytopenia. N Engl J Med 1988;319:1374-1378.
84. Bussel JB, McFarland JG, Berkowitz RL: Antenatal management of fetal alloimmune and autoimmune thrombocytopenia. Transfus Med Rev 1990;4:149-162.
85. Bussel JB, Skupski DW, MacFarland JG: Fetal alloimmune thrombocytopenia: consensus and controversy. J Matern Fetal Med 1996;5:281-292.
86. Bussel JB, Berkowitz RL, Lynch L, Lesser ML, Paidas MJ, Huang CL, McFarland JG: Antenatal management of alloimmune thrombocytopenia with intravenous gamma-globulin: a randomized trial of the addition of low-dose steroid to intravenous gamma-globulin. Am J Obstet Gynecol 1996;174:1414-1423.
87. Rothenberger S: Neonatal alloimmune thrombocytopenia. Ther Apher 2002;6:32-35.
88. Branch DW, Porter TF, Paidas MJ, Belfort MA, Gonik B: Obstetric uses of intravenous immunoglobulin: successes, failures, and promises. J Allergy Clin Immunol 2001;108:S133-S138.
89. NIH consensus conference. Intravenous immunoglobulin. Prevention and treatment of disease. JAMA 1990;264:3189-3193.
90. de Albuquerque Campos R, Sato MN, da Silva Duarte AJ: IgG anti-IgA subclasses in common variable immunodeficiency and association with severe adverse reactions to intravenous immunoglobulin therapy. J Clin Immunol 2000;20:77-82.
91. Eijkhout HW, van den Broek PJ, van der Meer JW: Substitution therapy in immunodeficient patients with anti-IgA antibodies or severe adverse reactions to previous immunoglobulin therapy. Neth J Med 2003;61:213-217.
92. Salama A, Schwind P, Schonhage K, Genth R, Cotting C, Hustinx H, Krieg R, Nydegger U, Aebischer I: Rapid detection of antibodies to immunoglobulin A molecules by using the particle gel immunoassay. Vox Sang 2001;81:45-48.
93. Schleis T, Siegel J: Formulary considerations for IGIV products. US Pharmacist, April 2005.
94. Dalakas MC: Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology 2002;59:S13-S21.
95. Braun-Moscovici Y, Furst DE: Immunoglobulin for rheumatic diseases in the twenty-first century: take it or leave it? Curr Opin Rheumatol 2003;15:237-245.
96. Ahmed AR: Treatment of autoimmune mucocutaneous blistering diseases with intravenous immunoglobulin therapy. Expert Opin Investig Drugs 2004;13:1019-1032.
97. Ratko TA, Burnett DA, Foulke GE, Matuszewski KA, Sacher RA: Recommendations for off-label use of intravenously administered immunoglobulin preparations. University Hospital Consortium Expert Panel for Off-Label Use of Polyvalent Intravenously Administered Immunoglobulin Preparations. JAMA 1995;273:1865-1870.
98. Pildal J, Gotzsche PC: Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review. Clin Infect Dis 2004;39:38-46.